Intercept Pharmaceuticals Stock Price To Earning
| ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Price To Earning Analysis
Intercept Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Intercept Pharmaceuticals Price To Earning | (3.88) X |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Intercept Pharmaceuticals has a Price To Earning of -3.88 times. This is 115.02% lower than that of the Biotechnology sector and 178.7% lower than that of the Health Care industry. The price to earning for all United States stocks is 113.51% higher than that of the company.
Intercept Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Intercept Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X | |||
| Price To Book | 44.19 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 285.71 M | |||
| Gross Profit | 284.73 M | |||
| EBITDA | (61.7 M) | |||
| Net Income | (174.86 M) | |||
| Cash And Equivalents | 404.78 M | |||
| Cash Per Share | 13.58 X | |||
| Total Debt | 332.67 M | |||
| Debt To Equity | 411.20 % | |||
| Current Ratio | 3.22 X | |||
| Book Value Per Share | 1.72 X | |||
| Cash Flow From Operations | (26.78 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (4.26) X | |||
| Price To Earnings To Growth | (0.69) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 341 | |||
| Beta | 0.88 | |||
| Market Capitalization | 794.36 M | |||
| Total Asset | 553.71 M | |||
| Retained Earnings | (2.14 B) | |||
| Working Capital | 310.05 M | |||
| Current Asset | 641.69 M | |||
| Current Liabilities | 47.37 M | |||
| Z Score | -3.15 | |||
| Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |